This review discusses the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults and compares it with the 2014 National Lipid Association (NLA) Recommendations for Patient-Centered Management of Dyslipidemia. The review discusses some of the distinctions between the guidelines, including how to determine a patient's atherosclerotic cardiovascular disease risk, the role of lipoprotein treatment targets, the importance of moderate- and high-intensity statin therapy, and the use of nonstatin therapy in light of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) trial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccl.2015.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patterns and predictors of statin therapy after ischemic stroke and TIA: insights from the LIPYDS multicenter study.
Neurol Sci
January 2025
Department of Neurology and Stroke Unit, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, Milan, 20162, Italy.
Background: Patients with ischemic stroke (IS) or TIA face an elevated cardiovascular risk, warranting intensive lipid-lowering therapy. Despite recommendations, adherence to guidelines is suboptimal, leading to frequent undertreatment. This study aims to evaluate the statin use after IS and TIA.
View Article and Find Full Text PDFIgE and cardiac disease.
Acta Physiol (Oxf)
February 2025
Department of Physiology, Pharmacology and Toxicology, West Virginia University, Morgantown, West Virginia, USA.
IgE acts primarily via the high affinity IgE receptor (FcεRI) and is central to immediate hypersensitivity reactions (anaphylaxis). However, IgE is also important in the development of chronic hypersensitivity reactions (allergy). In the cardiovascular system, numerous clinical studies have investigated serum IgE levels, mainly in the context of myocardial infarction, and have established a clear association between IgE and ischemic cardiac events.
View Article and Find Full Text PDFApplication of adipose tissue-derived stem cell therapy with a clinically relevant dose does not significantly affect atherosclerotic plaque characteristics in a streptozotocin-induced hyperglycaemia mouse model.
J Mol Cell Cardiol Plus
September 2024
Department of Pathology, Amsterdam University Medical Centres (AUMC), Location VUmc, Amsterdam, the Netherlands.
Aims: Diabetes mellitus (DM) induces increased inflammation of atherosclerotic plaques, resulting in elevated plaque instability. Mesenchymal stem cell (MSC) therapy was shown to decrease plaque size and increase stability in non-DM animal models. We now studied the effect of MSC therapy in a streptozotocin-induced hyperglycaemia mouse model using a clinically relevant dose of adipose tissue-derived MSCs (ASCs).
View Article and Find Full Text PDFIntroduction: In USA, six million individuals with Sub-Saharan ancestry carry two high-risk variants, which increase the risk for kidney diseases. Whether APOL1 high-risk variants are independent risk factors for cardiovascular diseases is unclear and requires further investigation.
Methods: We characterized a mouse model to investigate the role of APOL1 in dyslipidemia and cardiovascular diseases.
Axillary to Superior Mesenteric Artery Bypass as a Viable Solution for Chronic Mesenteric Ischemia.
Cureus
December 2024
Vascular Surgery, Carle Foundation Hospital, Urbana, USA.
Chronic mesenteric ischemia (CMI) is a progressive condition that primarily affects the elderly, causing chronic abdominal pain and malnutrition. Timely treatment is essential to prevent further deconditioning or bowel ischemia. Surgical repair options include both endovascular and open procedures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!